Table 1.
Parameter/agent | Caspofungin | Micafungin | Anidulafungin |
---|---|---|---|
cost-effectiveness in invasive candidiasis/candidemia | X | X | X |
cost-effectiveness in suspected infections | X | X | X |
Lowering the incidence of IRF | X | X | X |
cost-effectiveness in prophylaxis | X |
X = potential reduction of total treatment cost vs. more traditional antifungals.